Studying How Different Induction Drugs Affect Early Survival and Outcomes in Critically Ill Adults Needing Intubation

What this Trial Is About

Researchers are evaluating the safety and effectiveness of different induction agents used for tracheal intubation in critically ill adult patients. This retrospective cohort study aims to identify which agents may minimize complications and mortality during intubation, a vital procedure to support breathing and prevent aspiration in emergency and intensive care settings. The study responds to the need for clearer evidence about the best induction agents, considering patient differences and treatment combinations. The study compares four main induction agents Propofol, Midazolam, Etomidate, and Ketamine, which are commonly used in intensive care units. Clinical data about the use of these agents during intubation in surgical ICU patients will be collected and analyzed retrospectively. The study focuses on how each agent affects patient outcomes such as cardiovascular stability during intubation and early mortality. Participants are critically ill adults admitted to a surgical ICU who received one of the studied induction agents and have complete clinical records. Researchers will measure outcomes including all-cause mortality within seven days after intubation, cardiovascular collapse around the time of intubation, and overall clinical progression. The study will use hospital records to assess these outcomes, and participation involves a review of existing medical data without additional procedures.

Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients